Caliper forges strategic partnership with Seegene

Caliper Life Sciences president and CEO Kevin Hrusovsky said the deal will improve the economics of diagnostic testing and advance the worldwide implementation of personalised medicine.

"We believe that Seegene’s DPO technology enables sensitive and specific, highly multiplexed assays directly from clinical samples, significantly improving the economics of today for centralized and hospital based diagnostic testing," Hrusovsky added.

SeePlex assays will be marketed and distributed outside the US, for use with the LabChip Dx through Seegene’s extensive network of global distributors.

The companies will co-market Caliper’s LabChip Dx platform and Seegene’s complete line of multiplex diagnostic content.

The LabChip Dx system provides high throughput, multiplex, cost effective sample processing for discovery and validation of molecular and companion diagnostics.

Seegene’s Dual Priming Oligonucleotide (DPO) approach to PCR-based assays utilises a new technique for DNA priming which is structurally and functionally different from traditional PCR priming.

Seegene and Caliper will work together to commercialize selected diagnostic assays with improved sensitivity and specificity while reducing overall costs.